Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Toyota Global Sales Fall as China Demand Slumps 
OpenAI Rejects Apple Trade Secret Theft Claims 
France Targets Shein, Temu With Fast-Fashion Fees 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
CIA-Linked Investor Helped Quantum Systems Expand in US 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Add as a preferred source on Google
NEW YORK, March 26, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the following investor conference:
- Needham Healthcare Conference at 12:45 p.m. ET on Wednesday, March 28, 2018
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
